380 results on '"Cohen, Joshua M."'
Search Results
2. Wyoming
3. New Mexico
4. Methamphetamine use and adoption of preventive behaviors early in the COVID-19 pandemic among men who have sex with men in Los Angeles, California
5. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System
6. Osteosarcopenia and Mortality in Older Adults Undergoing Transcatheter Aortic Valve Replacement
7. Gender Considerations in Rhinoplasty
8. Verified Erasure Correction in Coq with MathComp and VST
9. State and Institutional Policies on In-State Resident Tuition and Financial Aid for Undocumented Students: Examining Constraints and Opportunities
10. Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
11. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
12. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
13. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
14. A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States
15. Facial Expansion: A Blueprint for Coverage
16. Subcutaneous Lateral Temporal Lift
17. Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020
18. Verified Erasure Correction in Coq with MathComp and VST
19. A Formalization of Core Why3 in Coq
20. Immunogenicity of biologic therapies for migraine: a review of current evidence
21. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
22. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
23. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
24. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial
25. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
26. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
27. Preauthorization Inconsistencies Prevail in Reduction Mammaplasty
28. Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds
29. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
30. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study
31. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study
32. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine
33. Effective Treatment of Platysma Bands with Neurotoxin
34. Methamphetamine use and adoption of preventive behaviors early in the COVID-19 pandemic among men who have sex with men in Los Angeles, California
35. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System
36. Burden of migraine in Brazil: A cross‐sectional real‐world study
37. Survival after Digit Replantation and Revascularization Is Not Affected by the Use of Interpositional Grafts during Arterial Repair
38. Is the Medial Sural Artery Perforator Flap a New Workhorse Flap? A Systematic Review and Meta-Analysis
39. Physician and patient preferences for dosing options in migraine prevention
40. Clinical characteristics and patient‐reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
41. Facial Expansion: A Blueprint for Coverage.
42. Advances in Upper Extremity Scleroderma Wound Care
43. Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
44. Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients With Migraine: A Pooled Analysis of Phase 3 Studies (P1-2.004)
45. Timing and Location of Injection-site Adverse Events With Fremanezumab in Patients With Migraine: A Pooled Analysis of Phase 3 Studies (P16-2.003)
46. Changes in Heart Rate and Blood Pressure in Participants Treated With Fremanezumab for Migraine: A Pooled Analysis of Phase 3 Studies (P3-2.003)
47. Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines
48. Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
49. Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction
50. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.